Clinerion and Swiss data analysis firm Datametrix will partner on real-world evidence (RWE) research to study and analyse the realities behind clinical trial practices and their outcomes.
The two companies will enable real-world data (RWD) research to analyse differential treatment outcomes to optimise patient care protocols, supporting hospital management and healthcare policymakers.
Datametrix CEO Ahmed El Rhali said: “We believe that data collected in an organised and simple manner, then analysed using the right analytical tools will empower pharmaceutical and biotechnology companies to bring better drugs to market faster.
“Together, Datametrix and Clinerion can power real-world evidence research and bring insights in the realities of clinical practice, which is acutely relevant for pharmaceutical industry, field-leading clinicians, hospital management, healthcare policymakers and, of course, patients.”
Under the strategic collaboration, Clinerion’s RWD will integrate with Datametrix’s analytical capabilities to support pharmaceutical firms with clinical study design optimisation in order to meet development needs while reflecting real patient populations.
This synergy is expected to help pharma companies in successful patient recruitment by allowing them to select sites with a large population of eligible patients. It will also help those sites to directly identify potential patients.
The synergy will also help in improving the accuracy of RWD comparative clinical studies by applying statistical models to define the RWD study endpoints.
Clinerion will be able to use their access to RWD to recruit patients to RWD comparative groups.
Clinerion Site & Patient Network Director Léon Van Wouwe said: “Clinerion and Datametrix are acutely aware that clinical trials are becoming more complex.
“This partnership presents an integrated clinical research offer, in which patients, investigators, research sites, pharma and other service providers integrate efforts to unite around one single purpose, to bring together all patients with all the available treatment options that may suit them, and so improve patient outcomes.”